Alphamab Oncology (9966.HK) traded up 2.11 % during a 24 hours period ending at 04:22 PM Central Europe on Tuesday 27th. One Alphamab Oncology stock can currently be bought for about HKD 6.46 on popular exchanges. Current supply of Alphamab Oncology stocks is 948.3 mn. Alphamab Oncology has a current market capitalization of HKD 6.4 bn and approximately HKD 9.4 mn worth of Alphamab Oncology was traded on exchanges in the last 24 hours. Since last month end, Alphamab Oncology has traded -15.38 % down. Simple moving average of last 200 days is at HKD 8.54. The highest price of past 52 weeks was recorded at HKD 12.2 on 04/20/2026. 52 weeks low was at HKD 5.87 on 10/23/2026.
Here is how related stocks have performed in the past 24 hours:
Shanxi Blue Flame (000968.SZ) traded flat 0 % and now trades at CNY 6.78. Current market capitalisation for Shanxi Blue Flame is CNY 6.5 bn. Shanxi Blue Flame has a current price to earnings ratio of 21.78.
Jsti (300284.SZ) traded flat 0 % and now trades at CNY 4.97. Jsti has a market capitalisation of CNY 6.5 bn. Jsti has a current price to earnings ratio of 849.18.
Bank Of Zhengzhou -H (6196.HK) traded flat 0 % and now trades at HKD 0.83. Bank Of Zhengzhou -H has a market capitalisation of HKD 7.7 bn. Bank Of Zhengzhou -H has a current price to earnings ratio of 4.5.
Caina (301122.SZ) traded flat 0 % and now trades at CNY 50.19. Current market capitalisation for Caina is CNY 6.5 bn. Current price/earnings ratio for Caina is 1,218.92. Caina Technology Co. Ltd. reported a notable improvement in its financial performance during the first nine months of 2026. The company’s revenue increased substantially, driven by higher sales across its product lines. Net profit attributable to shareholders nearly doubled year‑on‑year, reversing previous losses and reflecting successful operational adjustments. After excluding non‑recurring items, the company also achieved a positive net profit, marking a turnaround from the prior year’s deficit. Cash flow from operating activities saw a decline, yet the company’s earnings per share rose markedly. In the third quarter alone, revenue growth was even more pronounced, and the firm managed to convert prior losses into a modest profit, indicating progress in its cost management and product strategy. Overall, Caina Technology’s latest report highlights a strengthening profitability trajectory amid a rapidly expanding revenue base.
Jiangsu Zhengdan Chemical (300641.SZ) traded flat 0 % and now trades at CNY 11.93. Current market capitalisation for Jiangsu Zhengdan Chemical is CNY 6.6 bn. Jiangsu Zhengdan Chemical has a current price to earnings ratio of 20.46. Jiangsu Zhengdan Chemical Co., Ltd. released its third‑quarter 2026 report on October 26, confirming continued focus on core operations amid a tightening chemical industry environment. The company maintained stable revenue and profits, noting resilient performance during a period of heightened demand volatility and upstream price swings. Its balance sheet remained strong, with a low debt ratio and ample cash flow supporting ongoing research and development efforts. Zhengdan highlighted sustained investment in high‑value materials and new processes, aligning with the industry’s shift toward quality, green transformation and high‑end innovation. A mid‑year dividend plan was announced, providing shareholders with a distribution while preserving capital for future growth. The report underscored the firm’s confidence in its competitive position and its commitment to balancing shareholder returns with long‑term development.
About Alphamab Oncology
Alphamab Oncology is a health care company based in Suzhou, China. The company specializes in producing and selling drugs, with a focus on tumor immunobiology macromolecular targeted drugs and other products. Alphamab Oncology offers global services. You can learn more about their offerings by visiting their website at www.alphamabonc.com , and they are listed on the Hong Kong Stock Exchange.